Clinical Trial Update: Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide [Phase 1]

View source ↗

Summary

Phase 1 safety study of DFMO alone and in combination with etoposide in refractory or relapsed neuroblastoma has completed, with results posted on June 20, 2016…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• DFMO (difluoromethylornithine)
• Etoposide (Etoposide)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2016-06-20